LB Pharmaceuticals Inc

Healthcare · Biotechnology · United States

Last price 39.7 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 1.28B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New ...